Angle Share Price (AGL)

"Combined DNA Next Generation Sequencing of CTCs and CtDna from the same blood sample" soon. Personally, I don't see how a responsible Pharma Company can conduct a drug test trial involving metastasized cancer (any sort of cancer) without carrying out this NEW test before, during and after the treatment. Not to gather this information is to me is inconceivable. If, as I expect, Angle's services side can RNS their first order for this service soon the flood gates for orders will open. That is what I believe. That is why in the presentation Mr Newland called it a "game changer".

https://www.youtube.com/watch?v=cnQ6M05BiBY

All IMHO

I see these hitting 20.00 + in the short term and bought some more

EC

You rabbit on endlessly about the Jan 4th RNS., No authors, no referees etc,., simply an in house effort cobbled together collection of unpublished data. If, as you have told us, it is so important, why has it not been published in a reputable journal?

I know you do not answer questions, but others may have cause to wonder why these apparently incredibly important data have not been sent for publication, even in the world Journal of Irreproducible Results.

How on Earth can a responsible Pharma Company plan a cancer drug test trial involving metastasized cancer (any sort) without carrying out this NEW "Combined DNA Next Generation Sequencing of CTCs and CtDna from the same blood sample"? Before, during and after the drug trial. Think about it. A new test that measures the effect of said cancer treatment. It would be negligent for them not to, as simple as that. This will be massive for AGL IMHO.

The RNS:-

https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html

And the presentation:-

https://www.youtube.com/watch?v=cnQ6M05BiBY

All IMHO.

Results due soon. Also from November RNS

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"The Company expects strong revenue growth year-on-year. The cost savings from the streamlining of our clinical services business will now extend the forecast cash runway into Q2 2025 and we look forward to progressing the planned launches of new products and services to drive widespread adoption of the Company's Parsortix system to support precision medicine in cancer."